Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon- and ribavirin
Alimentary Pharmacology and Therapeutics, 05/18/2012
Chen Y et al. – Interleukin (IL)28B rs12979860 CC and rs8099917 TT are strong sustained virological response (SVR) predictors for pegylated interferon–alpha (PEG IFN–α)/ribavirin–treated hepatitis C virus (HCV)–1 patients, regardless of ethnicity. In HCV–2/3, rs12979860 CC has no SVR predictive value, but rs8099917 TT was slightly associated with SVR in Asians.Methods
- Meta-analysis was performed in 17 studies of rs12979860 CC vs. CT/TT and 17 of rs8099917 TT vs. TG/GG.
- Odds ratios (OR) and confidence intervals (95% CI) were calculated by fixed- or random-effects models.
- Heterogeneity, sensitivity analysis and publication bias were also assessed.
- Of 4252 Asian, Caucasian and African HCV patients analysed for rs12979860, SVR was more frequent in CC (vs. CT/TT; OR = 4.76, 95% CI: 3.15-7.20).
- Moreover, CC was associated with SVR for HCV genotype-1 or -4 infections (ORgenotype 1 = 5.52, 95% CI: 3.74-8.15; ORgenotype 4 = 8.11, 95% CI: 4.13–15.93), regardless of ethnicity. Of 4549 Caucasian and Asian HCV patients analysed for rs8099917, SVR was more frequent in TT (vs. TG/GG; OR = 3.31, 95% CI: 2.39-4.59).
- Moreover, TT was associated with SVR for HCV-1 (ORgenotype 1 = 4.28, 95% CI: 2.87-6.38).
- Rs8099917 TT predictive value was stronger in Asians (ORAsians = 8.09, 95% CI: 5.63-11.61; ORCaucasians = 3.00, 95% CI: 2.03-4.45).
- Ethnicity stratification revealed that rs8099917 TT had slight predictive value in Asian HCV-2/3 patients (OR = 1.99, 95% CI: 1.09-3.62).